Phone: 614/488-2118
Fax: 614/488-2647
1335 Dublin Rd., Suite 124A
Columbus, OH 43215
Member Sign in
HOME
MEMBERS
CANCER RESOURCES
ABOUT
EVENTS
EMPLOYMENT
CONTACT
Protocol Database
User Profile
Index of Forms
Ohio Partners for Cancer Control
Consortium Members
Treatment Sites & Physicians
Community Based Research Nurses
NCORP Videos
Our Team
Donate
HOME
MEMBERS
Protocol Database
User Profile
Index of Forms
CANCER RESOURCES
Ohio Partners for Cancer Control
ABOUT
Consortium Members
Treatment Sites & Physicians
Community Based Research Nurses
NCORP Videos
EVENTS
EMPLOYMENT
CONTACT
Our Team
Donate
Enter your search term
Protocol Categories
View All Protocols
PROTOCOL CREDENTIALS
Brain
Breast
CA Control
CCDR
Gastrointestinal
Genitourinary
GYN
Head and Neck
Hematology
Lung
Lymphoma
Melanoma / Skin-Other
Multiple Disease Sites
Observational
RT
Sarcoma
Unknown Primary
DCP
Multiple Disease Sites
Alliance A151804
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
ECOG EAY131 MASTER
Molecular Analysis for Therapy Choice (MATCH)
ECOG EAY131 Subprotocol A
MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG EAY131 Subprotocol C1
MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG EAY131 Subprotocol C2
MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG EAY131 Subprotocol E
MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR 790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG EAY131 Subprotocol H
MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer)
ECOG EAY131 Subprotocol L
MATCH Treatment Subprotocol L : Phase II Study of MLN0128(TAK-228)in Patients with Tumors with mTOR Mutations, to be incorporated into the EAY131 Master Protocol in Addendum #7
ECOG EAY131 Subprotocol V
MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GITS, Renal Cell Carcinoma or Pancreatic Neuroendocine Tumor)
ECOG EAY131 Subprotocol Z1E
MATCH Treatment Subprotocol Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG EAY131 Subprotocol Z1G
MATCH Treatment Subprotocol Z1G: Phase 2 STudy of Copanlisib in Patients with Tumors with PTEN Loss by IHC and Any PTEN Sequencing Result
ECOG EAY131 Subprotocol Z1M
MATCH Treatment Subprotocol Z1M: EAY131-Z1M: Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients with LAG-3+ Tumors with Mismatch Repair Deficiency (MMR-d) after Progression on Anti-PD-1/PD-L1 Therapy.
NCI COVID-19
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
SWOG S1609
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors